Stryker director Mary Brainerd buys $26,736 in company stock

Mary K. Brainerd, a director at Stryker Corp. (NYSE:SYK), has recently increased her indirect holdings in the medical technology company through a series of purchases totaling $26,736. These transactions occurred on various dates between June 2019 and November 2022.

Ms. Brainerd acquired a total of 131 shares of Stryker common stock across multiple transactions. These purchases were made at prices ranging from $185.65 to $225.195 per share. The shares were primarily held indirectly through her husband’s revocable trust.The medical device maker, with a market capitalization of $119.95 billion, currently trades at $312.19 per share. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The company maintains a "GOOD" financial health score and holds a perfect Piotroski Score of 9, indicating strong financial strength. InvestingPro offers additional exclusive tips and a comprehensive Pro Research Report for deeper analysis.

Separately, the filing also reported a disposition of 7,790 shares of Stryker common stock. No corresponding sale price was provided for this specific transaction. The report also detailed transfers between indirect ownership forms, noting that 11 shares initially acquired in Ms. Brainerd’s IRA were later transferred to her husband’s revocable trust on September 1, 2026. These 11 shares are included in the total holdings reported under the trust.

In other recent news, Stryker Corporation reported its second-quarter 2026 results, exceeding Wall Street expectations with adjusted earnings of $3.69 per share on revenue of $6.6 billion. This performance surpassed analyst estimates of $3.49 per share and $6.58 billion in revenue. The company experienced a recovery in sales following a cybersecurity incident earlier in the year, although concerns remain about the narrow full-year outlook. Wolfe Research responded to these strong results by raising its price target for Stryker to $375 from $350, maintaining an Outperform rating. The firm noted a 9% organic revenue growth for the quarter and a year-over-year earnings per share increase of 18%, which exceeded consensus estimates by 6%.

On the other hand, Citizens adjusted its price target for Stryker to $400 from $440, while still maintaining a Market Outperform rating. This decision was influenced by operational challenges, including a cyberattack and supply chain disruptions in the first half of fiscal 2026. Despite these hurdles, Stryker increased the low end of its fiscal 2026 organic growth guidance by 30 basis points and its earnings per share guidance by $0.05. These developments reflect the company’s resilience and adjustments amidst ongoing operational challenges.